Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
MDM2 amplification
i
Other names:
MDM2, HDM2, MGC5370, MDM2 proto-oncogene, E3 ubiquitin protein ligase
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4193
Related biomarkers:
Expression
Mutation
CNA
Others
‹
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
MDM2 amplification
Liposarcoma
MDM2 amplification
Liposarcoma
APG-115
Sensitive: C2 – Inclusion Criteria
APG-115
Sensitive
:
C2
APG-115
Sensitive: C2 – Inclusion Criteria
APG-115
Sensitive
:
C2
MDM2 amplification
Solid Tumor
MDM2 amplification
Solid Tumor
RAIN-32
Sensitive: C2 – Inclusion Criteria
RAIN-32
Sensitive
:
C2
RAIN-32
Sensitive: C2 – Inclusion Criteria
RAIN-32
Sensitive
:
C2
MDM2 amplification
Liposarcoma
MDM2 amplification
Liposarcoma
RAIN-32
Sensitive: C2 – Inclusion Criteria
RAIN-32
Sensitive
:
C2
RAIN-32
Sensitive: C2 – Inclusion Criteria
RAIN-32
Sensitive
:
C2
MDM2 amplification
Liposarcoma
MDM2 amplification
Liposarcoma
BI 907828
Sensitive: C2 – Inclusion Criteria
BI 907828
Sensitive
:
C2
BI 907828
Sensitive: C2 – Inclusion Criteria
BI 907828
Sensitive
:
C2
MDM2 amplification
Sarcoma
MDM2 amplification
Sarcoma
RAIN-32
Sensitive: C2 – Inclusion Criteria
RAIN-32
Sensitive
:
C2
RAIN-32
Sensitive: C2 – Inclusion Criteria
RAIN-32
Sensitive
:
C2
MDM2 amplification
Solid Tumor
MDM2 amplification
Solid Tumor
BI 907828
Sensitive: C2 – Inclusion Criteria
BI 907828
Sensitive
:
C2
BI 907828
Sensitive: C2 – Inclusion Criteria
BI 907828
Sensitive
:
C2
MDM2 amplification
Cholangiocarcinoma
MDM2 amplification
Cholangiocarcinoma
BI 907828
Sensitive: C2 – Inclusion Criteria
BI 907828
Sensitive
:
C2
BI 907828
Sensitive: C2 – Inclusion Criteria
BI 907828
Sensitive
:
C2
MDM2 amplification
Biliary Tract Cancer
MDM2 amplification
Biliary Tract Cancer
BI 907828
Sensitive: C2 – Inclusion Criteria
BI 907828
Sensitive
:
C2
BI 907828
Sensitive: C2 – Inclusion Criteria
BI 907828
Sensitive
:
C2
MDM2 amplification
Mucosal Melanoma
MDM2 amplification
Mucosal Melanoma
ipilimumab
Resistant: C3 – Early Trials
ipilimumab
Resistant
:
C3
ipilimumab
Resistant: C3 – Early Trials
ipilimumab
Resistant
:
C3
MDM2 amplification
Mucosal Melanoma
MDM2 amplification
Mucosal Melanoma
nivolumab + ipilimumab
Resistant: C3 – Early Trials
nivolumab + ipilimumab
Resistant
:
C3
nivolumab + ipilimumab
Resistant: C3 – Early Trials
nivolumab + ipilimumab
Resistant
:
C3
MDM2 amplification
Mucosal Melanoma
MDM2 amplification
Mucosal Melanoma
nivolumab
Resistant: C3 – Early Trials
nivolumab
Resistant
:
C3
nivolumab
Resistant: C3 – Early Trials
nivolumab
Resistant
:
C3
MDM2 amplification
Mucosal Melanoma
MDM2 amplification
Mucosal Melanoma
pembrolizumab
Resistant: C3 – Early Trials
pembrolizumab
Resistant
:
C3
pembrolizumab
Resistant: C3 – Early Trials
pembrolizumab
Resistant
:
C3
MDM2 amplification
Gastric Adenocarcinoma
MDM2 amplification
Gastric Adenocarcinoma
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
MDM2 amplification
Diffuse Large B Cell Lymphoma
MDM2 amplification
Diffuse Large B Cell Lymphoma
Resistant: C3 – Early Trials
Resistant
:
C3
Resistant: C3 – Early Trials
Resistant
:
C3
MDM2 amplification
Solid Tumor
MDM2 amplification
Solid Tumor
BI 907828 + BI 754091
Sensitive: C3 – Early Trials
BI 907828 + BI 754091
Sensitive
:
C3
BI 907828 + BI 754091
Sensitive: C3 – Early Trials
BI 907828 + BI 754091
Sensitive
:
C3
MDM2 amplification
Ampulla of Vater Carcinoma
MDM2 amplification
Ampulla of Vater Carcinoma
BI 907828
Sensitive: C3 – Early Trials
BI 907828
Sensitive
:
C3
BI 907828
Sensitive: C3 – Early Trials
BI 907828
Sensitive
:
C3
MDM2 amplification
Melanoma
MDM2 amplification
Melanoma
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
MDM2 amplification
Soft Tissue Sarcoma
MDM2 amplification
Soft Tissue Sarcoma
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
MDM2 amplification
Triple Negative Breast Cancer
MDM2 amplification
Triple Negative Breast Cancer
pembrolizumab
Resistant: C4 – Case Studies
pembrolizumab
Resistant
:
C4
pembrolizumab
Resistant: C4 – Case Studies
pembrolizumab
Resistant
:
C4
MDM2 amplification
Hormone Receptor Positive Breast Cancer
MDM2 amplification
Hormone Receptor Positive Breast Cancer
RAIN-32
Sensitive: D – Preclinical
RAIN-32
Sensitive
:
D
RAIN-32
Sensitive: D – Preclinical
RAIN-32
Sensitive
:
D
MDM2 amplification
Glioblastoma
MDM2 amplification
Glioblastoma
BI 907828
Sensitive: D – Preclinical
BI 907828
Sensitive
:
D
BI 907828
Sensitive: D – Preclinical
BI 907828
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login